Favipiravir
- Generic Name
- Favipiravir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
- Associated Therapies
- -
Favipiravir Therapy in Adults With Mild COVID-19
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 231
- Registration Number
- NCT04464408
- Locations
- 🇸🇦
Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia
🇸🇦King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia
🇸🇦Primary Health Care-Al Mansoura, Riyadh, Saudi Arabia
Control of COVID-19 Outbreaks in Long Term Care
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Appili Therapeutics Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT04448119
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
An Adaptive Clinical Trial of Antivirals for COVID-19 Infection
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 190
- Registration Number
- NCT04445467
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Chromis LLC
- Target Recruit Count
- 330
- Registration Number
- NCT04434248
- Locations
- 🇷🇺
Yakutsk City Clinical Hospital, Yakutsk, Russian Federation
🇷🇺Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation
🇷🇺Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation
A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT04425460
- Locations
- 🇷🇴
"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania
🇷🇴Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania
🇷🇴Emergency County Hospital "Pius Brinzeu"Timisoara, Timişoara, Timis, Romania
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
- Conditions
- Favipiravir (Favipira)COVID-19
- Interventions
- Drug: Only Standard TreatmentDrug: Favipiravir
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Bangladesh Medical Research Council (BMRC)
- Target Recruit Count
- 50
- Registration Number
- NCT04402203
- Locations
- 🇧🇩
Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
- Conditions
- SARS-CoV 2COVID-19
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 150
- Registration Number
- NCT04387760
- Locations
- 🇧🇭
Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
- Conditions
- HydroxychloroquineCOVID-19FavipiravirKaletraLopinavir/Ritonavir
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Baqiyatallah Medical Sciences University
- Target Recruit Count
- 40
- Registration Number
- NCT04376814
- Locations
- 🇮🇷
Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
Early Intervention in COVID-19: Favipiravir Verses Standard Care
- Conditions
- Coronavirus Infection
- Interventions
- Other: Standard of care managementDrug: Favipiravir
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Chelsea and Westminster NHS Foundation Trust
- Target Recruit Count
- 502
- Registration Number
- NCT04373733
- Locations
- 🇧🇷
Grupo Hospitalar Conceição, Porto Alegre, Brazil
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico
🇬🇧Hull University Teaching Hospitals NHS Trust - Castle Hill Hospital, Hull, United Kingdom
Favipiravir in Hospitalized COVID-19 Patients
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04359615
- Locations
- 🇮🇷
Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.